[PDF][PDF] Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort …
A Grothey, MM Sugrue, DM Purdie, W Dong… - J Clin …, 2008 - researchgate.net
J Clin Oncol, 2008•researchgate.net
Purpose Bevacizumab provides a survival benefit in first-and second-line metastatic
colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study
(Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients
who had mCRC, a longer-thanexpected overall survival (OS) of 25.1 months was reported.
The association between various preand post-treatment factors (including the use of
bevacizumab beyond first progression [BBP]) and survival was examined.
colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study
(Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients
who had mCRC, a longer-thanexpected overall survival (OS) of 25.1 months was reported.
The association between various preand post-treatment factors (including the use of
bevacizumab beyond first progression [BBP]) and survival was examined.
Purpose
Bevacizumab provides a survival benefit in first-and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effects and Safety [BRiTE]) in patients who had mCRC, a longer-thanexpected overall survival (OS) of 25.1 months was reported. The association between various preand post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined.
researchgate.net